Therefore, we aimed to test the hypothesis that chronic viral hepatitis might modify the reported associations between exogenous insulin analogues and HCC risks in a nationwide population with newly diagnosed diabetes on any antidiabetic agents, before and after excluding chronic viral hepatitis. This evidence concerns the gene INS and animal viral hepatitis.